The short-term effects of intravitreal aflibercept injections and dexamethasone implant on ocular hemodynamics in retinal vein occlusions

Figures & data

Figure 1 Flowchart of the study.Abbreviations: RVO, Retinal vein occlusion; BRVO, Branch retinal vein occlusion, CRVO, Central retinal vein occlusion; EDV, End diastolic volume; PSV, Peak systolic volume; Vmean, Average blood velocity; RI, Resistive index.

Table 1 The characteristics of patients

	CRVO (n:21)	BRVO (n:26)	All groups (n:47)
Age	72.30±2.40	55.42±3.25	66.55±0.82
Sex (M/F)	11/10	14/12	25/22
Hypertension	15	19	34
Duration of macular edema (months)	2.05±0.5	2.26±0.9	2.15±0.6
IOP	16.10±1.32	15.50±0.93	15.8±1.12
Aflibercept/dexamethasone	10/11	26/–	36/11

Table 2 Baseline hemodynamic characteristics in central retinal vein occlusion

CRVO	Affected eye	Unaffected eye	P-value
Ophthalmic artery
PSV	40.73±0.30	44.5±4.70	0.247
EDV	9.00±1.43	12.5±1.34	0.475
Vort	26.0±2.17	28.5±2.78	0.266
RI	2.86±0.34	2.98±0.33	0.594
Central Retinal Artery
PSV	18.50±2.59	22.73±2.97	0.066
EDV	6.59±0.85	8.0±1.04	0.025
Vort	12.55±1.65	15.36±1.9	0.041
RI	1.95±0.25	1.88±0.29	0.790

Table 3 Changes in hemodynamic parameters in central retinal vein occlusion group after injection

CRVO	Before injection	1st week	1st month	P-value
Ophthalmic artery
PSV	40.73±3.3	31.91±1.68	31.27±1.85	0.037
EDV	10.05±1.34	9.36±1.01	9.45±0.89	0.069
Vort	26.0±2.17	18.77±2.21	19.45±1.62	0.029
RI	2.86±0.34	2.76±0.34	2.52±0.29	0.931
Central Retinal Artery
PSV	18.50±2.59	14.91±1.73	11.73±1.32	0.002
EDV	6.59±0.85	6.0±0.79	4.45±0.58	0.002
Vort	12.55±1.65	10.64±1.15	8.09±0.92	0.001
RI	1.95±0.25	1.71±0.35	1.86±0.33	0.913

Table 4 The comparison of the hemodynamic parameters in patients who received anti-VEGF or dexamethasone implant

CRVO	Aflibercept group	Dexamethasone group	P-value
Ophthalmic artery
1st week PSV	30.4±2.54	33.17±2.32	0.429
EDV	8.4±1.72	10.17±1.22	0.429
Vort	15.3±4.26	21.67±1.44	0.126
RI	3.1±0.61	2.47±0.39	0.329
1st month PSV	32.2±2.44	30.5±2.88	0.537
EDV	8.6±0.98	10.17±1.42	0.429
Vort	20.4±1.53	18.67±2.94	0.429
RI	2.91±0.42	2.2±0.38	0.537
Central Retinal Artery
1st week PSV	15.2±2.85	14.67±2.36	0.429
EDV	5.40±1.33	6.5±0.99	1.000
Vort	10.7±1.82	10.58±1.61	1.000
RI	2.2±0.56	1.31±0.24	0.177
1st month PSV	11.0±1.14	12.33±2.39	0.792
EDV	3.8±0.58	5.0±0.93	0.429
Vort	7.4±0.68	8.67±1.63	1.000
RI	2.24±0.64	1.54±0.28	0.537

Table 5 Baseline hemodynamic characteristics in branch retinal vein occlusion

BRVO	Affected eye	Unaffected eye	P-value
Ophthalmic artery
PSV	38.5±3.11	34.44±3.26	0.132
EDV	12.56±1.26	12.63±1.62	0.955
Vmean	25.53±2.11	23.53±2.42	0.325
RI	2.30±0.16	2.08±0,20	0.211
Central retinal artery
PSV	18.63±2.94	20.03±3.01	0.247
EDV	6.50±1.13	5.98±1.32	0.466
Vmean	12.56±2.02	14.23±2.40	0.513
RI	2.02±0.19	2.05±0.19	0.820

Table 6 Changes in hemodynamic parameters in branch retinal vein occlusion group after injection

BRVO	Before injection	1st week	1st month	P-value
Ophthalmic artery
PSV	38.5±3.11	35.31±2.14	34.38±1.94	0.627
EDV	12.56±1.26	12.94±0.92	12.50±1.18	0.938
Vort	25.53±2.11	24.13±1.40	23.31±1.51	0.405
RI	2.30±0.16	1.89±0.24	1.97±0.18	0.099
Central Retinal Artery
PSV	18.63±2.94	13.69±1.56	10.81±0.51	0.024
EDV	6.50±1.13	5.19±0.84	3.44±0.20	0.020
Vort	12.56±2.02	9.44±1.17	7.22±0.40	0.066
RI	2.02±0.19	1.91±0.22	2.22±0.14	0.099